Get started
Author

Kyle Landskroner

Observed names: K. A. Landskroner, K. Landskroner, K.A. LANDSKRONER, K.A. Landskroner, Kyle A Landskroner, Kyle A. Landskroner
ORCID: 0009-0003-4141-5245
Observed ORCID: 0009-0003-4141-5245
OpenAlex ID: A5036886965
Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist
2011 · Shirin Bruderer, Päivi Äänismaa, et al. · The AAPS Journal · 67
PDF
Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension
2015 · Marc Iglarz, Kyle Landskroner, et al. · Journal of Cardiovascular Pharmacology · 38
Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?
2004 · Valery V Novokhatny, Gary J Jesmok, et al. · Trends in Pharmacological Sciences · 31
Thromboelastography measurements of whole blood from factor VIII‐deficient mice supplemented with rFVIII
2005 · K. A. Landskroner, N. C. Olson, et al. · Haemophilia · 19
Optimization Of Tissue Targeting Properties Of Macitentan, A New Dual Endothelin Receptor Antagonist, Improves Its Efficacy In A Rat Model Of Pulmonary Fibrosis Associated With Pulmonary Arterial Hypertension
2011 · Marc Iglarz, Kyle Landskroner, et al. · American Journal of Respiratory and Critical Care Medicine · 16
Cross-Species Pharmacologic Evaluation of Plasmin as a Direct-Acting Thrombolytic Agent: Ex Vivo Evaluation for Large Animal Model Development
2005 · Kyle Landskroner, Neil Olson, et al. · Journal of Vascular and Interventional Radiology · 16
Surgical and pharmacological animal models used in drug metabolism and pharmacokinetics
2011 · K.A. Landskroner, P. Hess, et al. · Xenobiotica · 10
Enhanced factor VIII activity measurements using ROTEG and factor VIII–/– mice whole blood
2004 · K.A. LANDSKRONER, N.C. OLSON, et al. · Journal of Thrombosis and Haemostasis · 5
Site-specific Pegylation of Rfviii Results in Prolonged in Vivo Efficacy
2007 · J.E. Murphy, C. Pan, et al. · Journal of Thrombosis and Haemostasis · 4
Towards a New Therapy for Hemophilia A: Evaluation of Multiple Approaches To Prolong the In Vivo Efficacy of Recombinant Factor VIII.
2006 · John E. Murphy, Clark Pan, et al. · Blood · 3
AZ-3102 significantly increases survival and decreases neuroinflammation in a mouse model of Sandhoff disease
2023 · Kyle Landskroner, Kshitiz Singh, et al. · Molecular Genetics and Metabolism · 2
Evaluation of PEG-FVIII Molecules with Prolonged Half-Lives in a Murine FVIII-Dependent Bleeding Model.
2006 · Kyle A. Landskroner, Zhi-Hua Cui, et al. · Blood · 2
Therapeutic Effects of Nizubaglustat in a Mouse Model of GM2 Gangliosidosis
2026 · Kyle Landskroner, Kshitiz Singh, et al. · Journal of Inherited Metabolic Disease · 1
A Pharmacologic Evaluation of BAY 79-4980 (Liposome-Formulated Kogenate® FS) in the Hemophilia A Mouse.
2006 · Gary Jesmok, Zhi-Hua Cui, et al. · Blood · 1
Nizubaglustat, a novel GCS and NLGase inhibitor significantly increases survival in a mouse model of GM1 gangliosidosis
2025 · Kyle Landskroner, Melissa D. Mitchell, et al. · Molecular Genetics and Metabolism
Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension
2011 · Marc Iglarz, Kyle Landskroner, et al. · European Respiratory Journal
Thrombosis and thrombolysis : emphasis on hemophilia and effect of clot dissolution with plasmin.
2006 · Kyle Landskroner · NCSU Libraries Repository (North Carolina State University Libraries)
PDF
Works count: 17
Citation count: 215
H-index: 7
I10-index: 7
Year
Topic
Type